( Provides Update to Timeline for Second ...)Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial,Health

CHICAGO, July 02, 2007 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced the confirmation of supplemental efficacy data from Trial CL-06, the first of two pivotal Phase 3 clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day antibiotic, for the treatment of community acquired pneumonia (CAP). The Company also provided an update to the projected timeline for announcement of top-line data from the second CAP study, Trial CL-05.

The Company is hosting a conference call and live webcast at 10:00 am (EDT) today, July 2, 2007 to discuss the available data from Trial CL-06. On the call will be members of the Advanced Life Sciences management team along with Donald E. Low, M.D., a recognized authority in microbiology and infectious diseases.

Statistical Considerations For Non-Inferiority

For statistical analysis pursuant to the Company's protocol and consistent with levels established in precedent FDA antibiotic drug approvals, non- inferiority at a 95% confidence interval is established when:

    -- The delta value is 10% or less on the lower bound and includes zero on

       the upper bound when the higher clinical cure rate of either

       cethromycin or Biaxin(R) is 90% or greater.

    -- The delta value is 15% or less on the lower bound and includes zero on

       the upper bound when the higher clinical cure rate of either

       cethromycin or Biaxin(R) is between 80% and 90%.

In addition, a p-value greater than 0.05 indicates that there is not a statistically significant difference between the study drug and comparator and supports non-inferiority.

The Company previously announced cethromycin's achievement of non-inferiority in the per protocol clinical cure rate compared to Biaxin(R) (clarithromycin) in CAP (cethro
'"/>